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However, consistent with their previous
studies, adult ghrelin-deficient animals
are unable to prevent hypoglycemia
developing in response to severe caloric
restriction. Importantly these studies also
highlight that replacement ghrelin dosing
to physiological levels is without effect
and that it is not until supraphysiological
dosing that changes in food intake are
observed. The complexity and extremity
of the fasting protocol used may explain
why it has not been supported in other
animal models and from prior studies in
humans.
Thesedatahighlight that not only are the
peripheral ghrelin-producing cells respon-
sive to glucose levels, but the GHSR cells,
predominantly in CNS, are likely to be
highly sensitive to glycemic levels to pro-
vide necessary feedback. This is also
consistent with existing CNS glucose-
sensing neural networks that respond to
release hormones and contribute to main-
taining energy requirements. Currently,
NPY/AgRP neurons are generally consid-
ered to be inhibited when glucose levels2 Cell Metabolism 20, July 1, 2014 ª2014 Elsrise (Chalmers et al., 2014) and activated
by ghrelin, suggesting that NPY/AgRP
neural function and glucose homeostasis
are maintained by a balance between
these two energy status signaling path-
ways. Whether function-specific NPY/
AgRP subgroups and circuits or specific
neurons with convergent signaling path-
ways are responsible for coordinating
this behavior is currently unclear. In addi-
tion, other functions ascribed to ghrelin
on the reproduction, stress, and immune
system response have not been tested
under these extreme environmental con-
ditions. Given that under such extreme
conditions behaviors geared toward
seeking and consuming food to contribute
to restoring glucose levels would be prior-
itized, understanding how ghrelin acts at
the level of the motivation and reward
pathways to control food intake also
needs to be addressed.REFERENCES
Chalmers, J.A., Jang, J.J., and Belsham, D.D.
(2014). Mol. Cell. Endocrinol. 382, 262–270.evier Inc.Kirchner, H., Heppner, K.M., Holland, J., Kabra, D.,
Tscho¨p, M.H., and Pfluger, P.T. (2013). PLoS ONE
8, e61822.
Kojima, M., and Kangawa, K. (2013). Endocr. Dev.
25, 1–4.
Li, R.L., Sherbet, D.P., Elsbernd, B.L., Goldstein,
J.L., Brown, M.S., and Zhao, T.J. (2012). J. Biol.
Chem. 287, 17942–17950.
McFarlane,M.R., Brown, M.S., Goldstein, J.L., and
Zhao, T.-J. (2014). Cell Metab. 20, this issue,
54–60.
Sun, Y., Ahmed, S., and Smith, R.G. (2003). Mol.
Cell. Biol. 23, 7973–7981.
Sun, Y., Asnicar, M., and Smith, R.G. (2007).
Neuroendocrinology 86, 215–228.
Wang, Q., Liu, C., Uchida, A., Chuang, J.-C.,
Walker, A., Liu, T., Osborne-Lawrence, S., Mason,
B.L., Mosher, C., Berglund, E.D., et al. (2014). Mol
Metab 3, 64–72.
Yi, C.-X., Heppner, K.M., Kirchner, H., Tong, J.,
Bielohuby, M., Gaylinn, B.D., Mu¨ller, T.D., Bartley,
E., Davis, H.W., Zhao, Y., et al. (2012). PLoSONE 7,
e32100.
Zhao, T.-J., Liang, G., Li, R.L., Xie, X., Sleeman,
M.W., Murphy, A.J., Valenzuela, D.M., Yanco-
poulos, G.D., Goldstein, J.L., and Brown, M.S.
(2010). Proc. Natl. Acad. Sci. USA 107, 7467–7472.Rejuvenation: It’s in Our BloodAlessandro Bitto1 and Matt Kaeberlein1,*
1Department of Pathology, University of Washington, Seattle, WA 98195-7470, USA
*Correspondence: kaeber@uw.edu
http://dx.doi.org/10.1016/j.cmet.2014.06.007
It has been known for some time that blood from youngmice can positively impact aged animals, while blood
from old mice has the opposite effect. Recent studies report that rejuvenating effects of young blood extend
to multiple tissues and have identified GDF11 and CCL11 as factors mediating these effects.Parabiosis is a surgical technique that
involves joining the circulatory system of
two animals such that they continuously
exchange blood and other circulating fac-
tors. About a decade ago, this method
was used to test whether the age of one
animal has effects on the health of its
partner through heterochronic parabiosis,
where a young mouse shares its circula-
tory system with an old mouse. Strikingly,
muscle stem cells and liver cells from
the young mouse functioned less well,while the same cells from the old mouse
showed molecular and functional evi-
dence for rejuvenation (Conboy et al.,
2005). Since then, similar effects have
been demonstrated in other tissues in-
cluding spinal cord (Ruckh et al., 2012),
heart (Loffredo et al., 2013), and brain
(Villeda et al., 2011). Recently, this work
has been extended by the finding that
injecting plasma from young mice is
sufficient to enhance cognitive function
and synaptic plasticity in aged mice(Villeda et al., 2014), and the identification
of two molecules as key mediators of the
beneficial and negative consequences
from heterochronic parabiosis (Figure 1),
growth differentiation factor 11 (GDF11)
(Katsimpardi et al., 2014; Sinha et al.,
2014), and C-C motif chemokine 11
(CCL11) (Villeda et al., 2011).
GDF11, a member of the TGF-b super-
family, declines in blood with age (Lof-
fredo et al., 2013), and restoration of
youthful levels of GDF11 are sufficient to
Figure 1. Opposing Effects of Heterochronic Parabiosis in Mice
Heterochronic parabiosis, in which a young mouse and an aged mouse share
circulatory systems, improves the health of the aged mouse while having
negative health consequences for the young mouse. GDF11 and CCL11
have recently been identified as two of the factors mediating these effects.
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Previewsenhance stem cell and tissue
function in heart (Loffredo
et al., 2013). In contrast, blood
levels of CCL11 increase with
age, and this increase ap-
pears to contribute to the
decline in neurogenesis and
function of neural stem cells
in the hippocampus (Villeda
et al., 2011). Now, two new
studies have found that
GDF11 also has beneficial
effects on skeletal muscle,
the subventricular nuclei, and
the hippocampus. Supple-
mentation with GDF11 alone
restored skeletal muscle
strength, physical endurance,
and regeneration followinginjury in aged mice (Sinha et al., 2014).
Similarly, old mice treated with GDF11
had improved olfactory perception, brain
vascularization, and neural stem cell func-
tion, which could translate into increased
protection of the nervous system against
age-related challenges (Katsimpardi
et al., 2014). Conversely, injecting CCL11
impaired learning and memory in young
mice, likely by reducing neurogenesis in
the hippocampus (Villeda et al., 2011). A
CCL11-neutralizing antibody abrogated
the negative effects of CCL11 treatment
in young mice, although it was not re-
ported whether the CCL11-neutralizing
antibody alone could improve function in
aged mice.
Another recent study suggests that the
fruit fly homolog of GDF11, myogliannin,
is secreted by muscle to regulate aging
in that organism (Demontis et al., 2014).
Demontis and colleagues found that
overexpression of the Mnt transcription
factor specifically in muscle was sufficient
to attenuate age-associated declines in
climbing ability and extend lifespan. Inter-
estingly, it also caused changes in nucle-
olar structure of both muscle and adipo-
cyte cells, suggesting that muscle Mnt
has both cell-autonomous and non-cell-
autonomous effects. Myogliannin was
identified as a secreted factor induced
by Mnt that mediates these effects, and
overexpression of myogliannin specif-
ically inmuscle extends lifespan. Although
it remains unclear whether myogliannin
functions similarly to GDF11 (myogliannin
is also homologous to myostatin and ap-
pears to function in some ways similarly
to myostatin), the observation that bothmyogliannin and GDF11 are secreted
factors that modulate aging-related phe-
notypes in flies and mice is intriguing.
Recent advances in aging research
have led to the identification of a small
but growing number of interventions that
enhance longevity and promote healthy
aging. For example, dietary restriction
and treatment with the mTOR inhibitor ra-
pamycin havebothbeen found to increase
lifespan in yeast, nematodes, fruit flies,
and mice. Such interventions, if they can
be successfully translated to people,
have the potential to dramatically impact
human health by simultaneously delaying
the onset and progression of multiple
age-related disorders (Kaeberlein, 2013).
As such, the discovery of systemic factors
that appear to modulate aging, such
asGDF11 andCCL11, has potentially pro-
found therapeutic implications. If similar
mechanisms occur in people, then
providing elderly individuals with plasma
from young individuals, or evenmore spe-
cifically with GDF11 or a CCL11-neutral-
izing antibody, may lead to improved
function of multiple organ systems. Given
that these approaches are essentially
restoring levels of our bodies’ own mole-
cules toward a more youthful state, they
may prove less prone to side effects
compared to pharmacological interven-
tions that slow aging, such as rapamycin.
On the other hand, altering the abun-
dance of specificmolecules in the context
of an aged system may have unantici-
pated effects that are different from the
young state. In this regard, it is rather sur-
prising that it hasn’t yet been reported
whether longer-term heterochronic para-Cell Metabolism 20, Julybiosis, or more specific treat-
ments in aged animals such
as young plasma or GDF11,
does in fact significantly
improve healthspan or life-
span of mice. This is impor-
tant both for evaluating
the effects of such interven-
tions in the context of aging
animals and for understand-
ing whether there are any
substantial negative side ef-
fects associated with such
treatments.
A related question is
whether continuous treat-
ment is required to fully reju-
venate tissues of aged mice,
or perhaps a transient expo-sure to these factors might be sufficient.
For example, injecting young plasma
into aged mice eight times over a period
of 24 days resulted in significant impro-
vements in hippocampal-dependent
learning and memory immediately follow-
ing treatment (Villeda et al., 2014), but it
is unclear whether these benefits persist
or are rapidly lost once treatment is
stopped. Finally, it remains to be ascer-
tained whether these systemic factors
act within well-known aging pathways,
such asmTOR and growth hormone/insu-
lin-IGF-1 signaling, or if they are effectors
of novel aging pathways. Indeed, the fac-
tors regulating the expression of GDF11
and CCL11, the tissues involved in their
production, their mechanism(s) of action,
and why their expression changes during
aging remain to be determined.
These discoveries set the stage for
interesting times, as many remaining
questions begin to be answered and
the translational potential is explored. It
seems likely that GDF11 and CCL11 are
only the first two in a series of circulating
molecules that will be found to influence
aging of different tissues. Whether these
are the most important or most potent
molecules remains to be seen. Future
studies in this area will likely bring forth
new and exciting knowledge about the
dynamics of aging and novel approaches
to regenerative medicine.REFERENCES
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Obesity promotes chronic activation of mTORC1 and is a known risk factor for hepatic injury, inflammation,
and carcinogenesis. In this issue, Umemura et al. (2014) demonstrate that a persistent reduction in hepatic
mTORC1activity alsopromotes cell damageand inflammation andsensitizes the liver to cancer development.Perhaps too much of everything is
as bad as too little.—Edna Ferber
This quotation from the 20th century
American novelist applies to so many
facets of human life, that most would
consider the statement more aphoristic
than enlightening. From a health perspec-
tive, there is no better supportive example
of this axiom than the human diet, which,
in different parts of the world, aptly illus-
trates the devastating consequences of
undernutrition (too little) or excessive
food intake (too much). In developed
countries, too much caloric intake
coupled with too little physical activity
have fueled an epidemic of obesity that
threatens to overburden the healthcare
systemwith sundry, life-threateningmala-
dies. One of the many unfortunate
sequelae of the obesity epidemic is an
increasing incidence of hepatocellular
carcinoma (HCC), an aggressive disease
with limited treatment options (Caldwell
et al., 2004). Environmental factors, such
as persistent hepatitis B or C infection,
are etiologically linked to the majority of
cases of HCC; however, chronic overnu-
trition is a rapidly emerging etiologic fac-
tor for this disease (Sanyal et al., 2010).
Preclinical and clinical studies indicate
that the nutrient-stimulated, rapamycin-sensitive mammalian target of rapamycin
complex 1 (mTORC1) is both activated
and functionally important for HCC devel-
opment and progression (Bhat et al.,
2013). Strong evidence that HCC is char-
acterized by ‘‘too much’’ mTORC1 activ-
ity prompted clinical trials with rapamycin
analogs (rapalogs), which unfortunately
yielded disappointing results. An ironic
twist to this negative outcome is that the
clinical use of rapalogs to reduce
mTORC1 activity in HCC is associated
with increased liver injury, which could,
in principle, promote disease progression
(Yamanaka et al., 2013).
A article in this issue of Cell Metabolism
explores the impact of reduced hepatic
mTORC1 activity on diet- and carcin-
ogen-induced inflammation and HCC
development in mice (Umemura et al.,
2014). In the initial studies, mice were
fed a high-fat diet (HFD), and mTORC1
activity was systemically reduced by
treatment of the animals with rapamycin.
Consistent with expectations, rapamycin
treatmentmarkedly suppressed the accu-
mulation of free fatty acids in the livers
of these mice; however, chronic drug
treatment elicited additional alterations
in liver physiology that were consistent
with an enhanced inflammatory response
and hepatocellular damage. A noteworthyeffect of this drugwas a dramatic increase
in serum interleukin-6 (IL-6), the source of
which was presumably, but not defini-
tively, proven to be the liver. Rapamycin
is a well-established inducer of auto-
phagy, and Umemura et al. (2014) noted
that the livers of drug-treated mice dis-
played changes in autophagy biomarkers
indicative of increased autophagic flux in
liver cells. Interestingly, previous studies
showed that autophagy is required for
the production of IL-6 during oncogene-
induced stress (Narita et al., 2011). Future
studies should examine whether auto-
phagy supports IL-6 production and the
consequent activation of STAT3 in
the rapamycin-treated liver. Nonetheless,
the contributions of autophagy to HCC
development seem very complex, with
tumor promotion or suppression as out-
comes, depending on the evolutionary
stage of the HCC (Cui et al., 2013).
In subsequent studies, Umemura et al.
(2014) employed an elegant genetic
approach to examine whether the effects
of reduced mTORC1 activity on hepato-
cyte physiology were truly cell autono-
mous. The authors generated mice
bearing a hepatocyte-specific knockout
of the Raptor gene, which is specifically
associatedwith and required formTORC1
function. The RaptorDhep mice were
